On 2 April 2026, The Economic Times reported that Bayer has reduced the upfront cost of Eylea® (aflibercept, 2mg) in India by about 44% to expand the eligible patient pool. According to the report, Eylea® will now be priced at Rs 29,998, down from Rs 53,141.
The announcement comes just under 2 months after Zydus’s Indian launch of its aflibercept biosimilar, Anyra™. Anyra™ is the first aflibercept 2mg biosimilar developed in India and was launched under licence from Regeneron and Bayer.
There is at least one other aflibercept biosimilar set to launch in India in 2026. In September 2025, Biocon’s Yesafili® was recommended by India’s Subject Expert Committee (SEC). This recommendation was subject to Biocon submitting a Phase IV clinical trial protocol to the Central Drugs Standard Control Organisation within 3 months of obtaining the marketing authorisation grant. In January 2026, Biocon reached a settlement and licence agreement with Regeneron and Bayer for Yesafili® in Europe and ROW, which permits Biocon to commercialise Yesafili® in India (and ROW other than UK, US and Canada) in H2 2026.
Eylea® was jointly developed by Bayer and Regeneron. Regeneron holds the exclusive rights to Eylea® in the US, while Bayer holds those outside the US, where the companies equally share the profits from sales of the products.